Digital PCR vs qPCR: Understanding the Differences in Molecular Quantification

Quantitative real-time PCR (qPCR) has become one of the most established technologies for detecting and quantifying nucleic acids.

Digital PCR (dPCR) approaches the same fundamental challenge differently.

Instead of measuring fluorescence continuously during amplification across a bulk reaction, digital PCR divides a sample into many individual reactions—or partitions—and determines how many are positive or negative for the target.

This difference in measurement architecture gives the two technologies different analytical characteristics and potential applications.

The question is therefore not:

“Is digital PCR better than qPCR?”

but:

“Which measurement approach is better suited to the analytical question?”

qPCR—also called real-time PCR—monitors fluorescence as amplification occurs.

During amplification, fluorescence increases as product accumulates.

The cycle at which the signal crosses a defined threshold is commonly expressed as a quantification cycle (Cq) or threshold cycle (Ct), depending on terminology and system.

Earlier detectable amplification generally corresponds to a greater starting amount of target than later amplification.

To translate this signal into meaningful quantitative information, the assay may use approaches such as standard curves, calibrators, reference genes or other validated quantitative frameworks.

qPCR is therefore not inherently limited to relative quantification. Depending on the assay design and calibration strategy, it can support relative or absolute quantitative approaches.

Digital PCR changes the measurement architecture.

Before or during the analytical process, the reaction is divided into many individual partitions.

Each partition contains either no target molecules or one or more target molecules according to their distribution in the sample.

Conceptually:

Following amplification, partitions are classified according to whether the target was detected.

If every positive partition contained exactly one target molecule, simply counting positive partitions would be sufficient.

In practice, some partitions can contain more than one target molecule.

Digital PCR therefore uses a statistical model—commonly based on Poisson distribution—to account for target occupancy and estimate the concentration of target molecules in the original reaction.

The fundamental difference

A useful way to think about the technologies is:

Both rely on nucleic-acid amplification.

But the route from amplification to quantitative measurement is different.

That difference influences how the technologies behave across different analytical applications.

The term absolute quantification is frequently associated with digital PCR.

In this context, it means that target concentration can be estimated from partition statistics without requiring a conventional external calibration curve to convert Cq/Ct values into concentration.

Conceptually:

This is an important analytical advantage.

But “absolute” should not be interpreted as meaning that the result is automatically free from measurement uncertainty or experimental bias.

Pre-analytical handling, nucleic-acid extraction, reverse transcription where applicable, assay design, partition volume, threshold setting and other factors can still influence the final measurement.

Absolute quantification does not mean absolute absence of analytical uncertainty.

Partitioning changes the analytical environment.

Imagine a sample containing a large amount of one sequence and a very small amount of another.

In a bulk reaction, both targets remain within the same overall analytical environment.

Digital PCR distributes nucleic-acid molecules across many smaller reactions.

This creates an opportunity to identify target-positive partitions against a large background population.

Depending on assay design and application, this can be particularly useful when measuring:

• low-abundance targets;
• rare sequence variants;
• small differences in target concentration;
• copy-number changes;
• low-level residual molecular targets.

The benefit, however, remains application dependent.

Partitioning alone does not guarantee that every assay will achieve better analytical performance.

No.

This is one of the most important misconceptions to avoid.

Analytical sensitivity depends on multiple factors, including:

If insufficient target molecules enter the reaction, partitioning cannot create molecules that were never sampled.

Likewise, poor extraction or assay design cannot automatically be rescued by changing PCR architecture.

Digital PCR may offer important advantages for certain low-level or rare-target measurements, but the relevant question is:

“Does the complete dPCR method provide the analytical performance required for this particular application?”

rather than:

“Is dPCR always more sensitive?”

Rare-variant analysis is one area where digital PCR can be particularly useful.

Consider a sample containing:

Partitioning distributes these molecules across many individual reactions.

With an appropriately designed assay, the variant can then be identified among a much larger background population.

This concept has applications in areas such as oncology research and molecular monitoring.

However, rare-variant performance still depends on factors including assay specificity, input quantity, partition number, false-positive background and the validated limit of detection.

Therefore:

Rare does not automatically mean detectable.

Digital PCR can also be useful for measuring copy-number differences.

The target of interest can be measured relative to an appropriate reference target, allowing the ratio between them to be estimated from partition-based measurements.

Potential applications include copy-number variation research and other genomic measurements where small differences in target abundance are important.

Again, the quality of the result depends on assay design, nucleic-acid quality and appropriate analytical validation.

One attraction of digital PCR is its ability to provide precise measurements under appropriate experimental conditions.

This can be valuable when the analytical question involves distinguishing relatively small differences in target concentration.

However, precision is influenced by the number of partitions, target occupancy and the number of molecules actually measured.

A dPCR result based on limited molecular input is not automatically highly precise simply because the technology is digital.

The experimental design must provide enough information to support the required measurement uncertainty.

Digital PCR also has an important practical consideration: partition occupancy.

If target concentration is very low, only a small number of partitions may become positive.

If target concentration is very high, a large proportion of partitions may contain target, eventually reducing the information available to estimate concentration accurately.

The useful quantitative range therefore depends partly on:

• number of partitions;
• partition volume;
• sample input;
• dilution;
• platform design.

qPCR can provide a broad quantitative range in many applications, while dPCR may require appropriate sample dilution or concentration management to position the target within an informative partition range.

This is another reason the technologies should not be described simply as old versus new.

Digital PCR can estimate target concentration without the conventional standard curve commonly used for absolute qPCR quantification.

That does not mean standards and reference materials become irrelevant.

Reference materials, controls and quality-assurance materials can remain important for:

• validating assay performance;
• assessing accuracy;
• monitoring reproducibility;
• comparing methods;
• supporting traceability;
• standardising clinically reported results where required.

This distinction becomes especially important when moving from analytical concentration to clinically standardised reporting.

BCR::ABL1 molecular monitoring in chronic myeloid leukemia provides an important example.

Digital PCR has been investigated and applied to BCR::ABL1 measurement, including low-level molecular detection.

However, clinically meaningful BCR::ABL1 monitoring has an additional requirement:

standardisation.

BCR::ABL1 results used for CML molecular response assessment are commonly expressed on the International Scale (IS) so that defined molecular response levels can be compared across validated testing systems and laboratories.

A dPCR platform’s ability to estimate target concentration does not, by itself, make the result an International Scale result.

Likewise:

Appropriate assay validation, reference materials, conversion or calibration approaches and the complete reporting framework remain important.

This distinction matters whenever analytical technologies are used for clinically standardised biomarkers.

Digital PCR has been studied for BCR::ABL1 measurement and continues to be evaluated and implemented in this field.

Published work has demonstrated strong correlation between dPCR and established real-time PCR approaches in selected settings, and more recent inter-laboratory work continues to examine how dPCR measurements can be harmonised for BCR::ABL1 International Scale reporting.

The important laboratory question is therefore not simply whether dPCR can detect BCR::ABL1.

It is:

“How is the complete assay validated, standardised and reported for its intended clinical use?”

For laboratories evaluating BCR::ABL1 applications, analytical sensitivity, molecular input, reference gene measurement, International Scale traceability, quality control and inter-laboratory comparability remain important considerations.

The emergence of digital PCR does not make qPCR obsolete.

qPCR remains a powerful and widely established molecular technology.

Depending on the application and system, strengths can include:

For many molecular diagnostic applications, qPCR may remain the most appropriate technology.

The value of dPCR appears when its measurement architecture addresses a requirement that matters for the particular assay.

Digital PCR may be particularly worth evaluating when the analytical requirement involves:

These are reasons to evaluate dPCR—not automatic guarantees that dPCR will outperform another method.

Rather than starting with the technology, begin with the measurement problem.